Actively Recruiting
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Led by Hyundai Pharm · Updated on 2024-12-13
160
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
CONDITIONS
Official Title
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 to 75 years
- Diagnosed with type 2 diabetes mellitus
- HbA1c between 7.0% and 10.0% while managed by diet and exercise alone for at least 8 weeks prior to screening
You will not qualify if you...
- Diagnosis of type 1 diabetes or another immune-mediated diabetes syndrome
- Body mass index (BMI) greater than 40 kg/m2
- C-peptide level less than 0.5 ng/mL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Korea University Anam Hospital
Seoul, South Korea
Actively Recruiting
Research Team
S
Sin Gon Kim Korea University Anam Hospital, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here